NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE – Single Technology Appraisal
Single Technology Appraisal
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
Dear stakeholders,
After very careful consideration, we have taken the decision to move the committee discussion for this appraisal to the meeting of the Highly Specialised Technologies Evaluation Committee on 14 February 2024. Please note that this topic will still be considered as a Single Technology Appraisal.
The discussion previously planned for 8 February 2024 will not be going ahead. The NICE website will be updated at 12pm (noon) tomorrow, Tuesday 12 December 2023.
This decision was taken to allow both this appraisal and the appraisal of exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015] – the same therapy in a different indication – to be considered by the same committee.
We will contact the selected experts separately regarding the change in date. If you have any questions or concerns please do get in touch.
Best wishes,
Celia
Celia Mayers (she/her)
Project Manager, Technology Appraisals & HST
Emma trained at St Barts and the Royal London School of Medicine, University of London and qualified in 2001 and is currently working as a Haematology Consultant between UCLH and the Whittington Hospital. She was Clinical Lecturer in Sickle Cell Disease at King’s College Hospital from 2009 to 2013 and during that time was awarded her PhD based on research into markers of severity and predictors of organ dysfunction in sickle cell disease. In 2013 she was awarded the Early Stage Investigator prize from the British Society of Haematology. She is the Haemoglobinopathy Coordinating Centre lead for North Central and West London, East Anglia and the South West and Central England.
John James OBE has 33 years of experience within the NHS including 4 CEO roles. He was Chair of the West London Cancer network (2002-2005) and Chair of the North West London Diabetes Network (2003-2004). 
Dr Subarna Chakravorty is a Paediatric Haematologist with a special interest in non-malignant haematology and stem cell transplant for haemoglobinopathy and non-malignant diseases. She joined King’s College Hospital as consultant in July 2015. Prior to that, Subarna led the Paediatric Haemoglobinopathy service at Imperial College Healthcare NHS Trust and the Imperial Paediatric Red Cell Disorders Network for 5 years, where she was also involved in the bone marrow transplant programme for paediatric haemoglobinopathy. Since 2021, Subarna has been involved in the adult sickle cell bone marrow transplant service at King’s College Hospital.
Dr Rachel Kesse-Adu is a consultant haematologist who qualified in medicine from Imperial College School of Medicine in 2002 and completed her specialist training in haematology at Kings College Hospital in London in 2012.